TGFB1 and hepatocellular carcinoma: Sorafenib is highly effective in suppressing EVs containing mRNA encoding CD63 and TGFB1 by CD90+ CSCs, which may be related to the ability of sorafenib to prolong overall survival in advanced HCC patients and suppress de novo metastasis.